Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis

Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatmen...

Full description

Bibliographic Details
Main Authors: William Tillett, Laura C. Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, Philip J. Mease
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X221140846
_version_ 1798005728628178944
author William Tillett
Laura C. Coates
Sandeep Kiri
Vanessa Taieb
Damon Willems
Philip J. Mease
author_facet William Tillett
Laura C. Coates
Sandeep Kiri
Vanessa Taieb
Damon Willems
Philip J. Mease
author_sort William Tillett
collection DOAJ
description Background: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9, <ACR20: 35.7; DAPSA remission (REM): 3.3, low disease activity (LDA): 9.8, moderate disease activity (MoDA): 22.4, high disease activity (HDA): 54.0. Improved disease control was also associated with fewer days affected by workplace presenteeism: ACR70: 5.6, ACR50 to <70: 19.3, ACR20 to <50: 71.2, < ACR20: 141.2; DAPSA REM: 5.7, LDA: 25.8, MoDA: 77.2, HDA: 223.6. Similar associations between greater disease control and improved productivity were observed for household absenteeism and presenteeism. Conclusion: This post hoc study demonstrates the cumulative workplace and household work productivity benefits for patients with PsA when achieving more stringent thresholds of disease control with certolizumab pegol treatment.
first_indexed 2024-04-11T12:43:42Z
format Article
id doaj.art-f7f96ae5debe47f0adb6ac18dbcad13e
institution Directory Open Access Journal
issn 1759-7218
language English
last_indexed 2024-04-11T12:43:42Z
publishDate 2022-12-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Musculoskeletal Disease
spelling doaj.art-f7f96ae5debe47f0adb6ac18dbcad13e2022-12-22T04:23:25ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182022-12-011410.1177/1759720X221140846Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritisWilliam TillettLaura C. CoatesSandeep KiriVanessa TaiebDamon WillemsPhilip J. MeaseBackground: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA. Objectives: This post hoc study investigated certolizumab pegol treatment impact on workplace and household productivity in patients with PsA, and assessed whether achievement of more stringent disease control was associated with greater improvements in productivity. Design: RAPID-PsA was a 216-week phase III trial. Methods: This post hoc study used a generalised estimating equations (GEE) model to examine the disease activity association, measured using American College of Rheumatology (ACR) and Disease Activity in PSoriatic Arthritis (DAPSA), and workplace and household productivity, assessed using an arthritis-specific Work Productivity Survey (WPS). The GEE model estimated the mean cumulative number of days patients meeting different disease control criteria were affected by absenteeism or presenteeism in the workplace and household. Results: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: 7.7, ACR20 to <50: 20.9, <ACR20: 35.7; DAPSA remission (REM): 3.3, low disease activity (LDA): 9.8, moderate disease activity (MoDA): 22.4, high disease activity (HDA): 54.0. Improved disease control was also associated with fewer days affected by workplace presenteeism: ACR70: 5.6, ACR50 to <70: 19.3, ACR20 to <50: 71.2, < ACR20: 141.2; DAPSA REM: 5.7, LDA: 25.8, MoDA: 77.2, HDA: 223.6. Similar associations between greater disease control and improved productivity were observed for household absenteeism and presenteeism. Conclusion: This post hoc study demonstrates the cumulative workplace and household work productivity benefits for patients with PsA when achieving more stringent thresholds of disease control with certolizumab pegol treatment.https://doi.org/10.1177/1759720X221140846
spellingShingle William Tillett
Laura C. Coates
Sandeep Kiri
Vanessa Taieb
Damon Willems
Philip J. Mease
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
Therapeutic Advances in Musculoskeletal Disease
title Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
title_full Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
title_fullStr Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
title_full_unstemmed Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
title_short Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
title_sort achievement of more stringent disease control is associated with reduced burden on workplace and household productivity results from long term certolizumab pegol treatment in patients with psoriatic arthritis
url https://doi.org/10.1177/1759720X221140846
work_keys_str_mv AT williamtillett achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis
AT lauraccoates achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis
AT sandeepkiri achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis
AT vanessataieb achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis
AT damonwillems achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis
AT philipjmease achievementofmorestringentdiseasecontrolisassociatedwithreducedburdenonworkplaceandhouseholdproductivityresultsfromlongtermcertolizumabpegoltreatmentinpatientswithpsoriaticarthritis